Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12116589 Treatment of amyotrophic lateral sclerosis (ALS)

Patent 12116589 was granted and assigned to Voyager Therapeutics on October, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Current Assignee

Voyager Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Qingmin Chen0

Joan R. Coates0

Holger Patzke0

Dinah Wen-Yee Sah0

Jinzhao Hou0

Date of Patent

October 15, 2024

0

Patent Application Number

178811930

Date Filed

August 4, 2022

0

Patent Citations

US Patent 9447433 Synthetic adeno-associated virus inverted terminal repeats

0

US Patent 10597660 Compositions and methods of treating amyotrophic lateral sclerosis (ALS)

0

US Patent 10689420 AAV's and uses thereof

0

US Patent 10731155 In vivo production of small interfering RNAs that mediate gene silencing

0

US Patent 10731178 CNS targeting AAV vectors and methods of use thereof

0

US Patent 10920227 Compositions and methods of treating amyotrophic lateral sclerosis (ALS)

0

US Patent 11193129 Modulatory polynucleotides

0

US Patent 11198873 Modulatory polynucleotides

0

...

Patent Primary Examiner

Amy Rose Hudson

0

CPC Code

0

0

Patent abstract

The present invention relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and/or canine degenerative myelopathy (DM).

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12116589 Treatment of amyotrophic lateral sclerosis (ALS)

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool